Consultant Clinical and Laboratory Haematologists - Melbourne Haematology Melbourne Haematology - clinical and laboratory trained haematologists providing comprehensive management of patients with all blood related conditions and disorders. https://melbournehaematology.com.au Tue, 07 Jul 2020 14:01:56 +1000 Joomla! - Open Source Content Management en-gb Associate Professor Philip Campbell https://melbournehaematology.com.au/haematologists/associate-professor-philip-campbell.html https://melbournehaematology.com.au/haematologists/associate-professor-philip-campbell.html Associate Professor Philip Campbell

Assoc Prof Philip Campbell consulting at: Geelong

Geelong Private Medical Centre
Suite 5, Level 3
73 Little Ryrie Street
Geelong VIC 3220
Tel: 03 5226 1675
Fax: 03 5226 1677

Map of Rooms LocationView Map of Room's Location

Private Hospital Accreditations
St John of God Hospital
Geelong Private Hospital


MB ChB FRCP FRACP FRCPath FRCPA

  • Clinical Associate Professor
    Deakin University Medical School
  • Andrew Love Cancer Centre
    Geelong Hospital, Barwon Health
  • Clinical Haematologist

Philip Campbell is a general haematologist with broad training and experience in malignant and non-malignant haematology.

His main clinical interests are malignant haematology (leukaemia, lymphoma, myeloma and autologous stem cell transplantation) and clinical research, particularly multi centre collaborative research in malignant haematology.


Assoc Prof Philip Campbell's areas of interest also include haematological oncology, clinical research and obstetric haematology.


Society Memberships

  • Haematology Society of Australia and New Zealand
  • British Society of Haematology
  • Australasian Leukaemia and Lymphoma Group
  • Australasian Society of Thrombosis and Haemostasis
  • Australasian Society of Blood Transfusion
  • Australasian Society of Bone Marrow Transplantation
  • American Society of Haematology.

Present Appointments:

October 2001 - Senior Staff Specialist, Clinical Haematology, The Andrew Love
Cancer Centre, Geelong Hospital, Geelong, Victoria, Australia

Clinical Tutor, University of Melbourne, Geelong and St. Vincent’s
Hospital Clinical School 2002-2009

Clinical Associate Professor, School of Medicine, Faculty of Health,
Medicine, Nursing and Behavioural Sciences, Deakin University


Publications

  1. Campbell PJ, Ryan KE, Olatunji P, Davies SC. Splenic regrowth in sickle cell anaemia following hypertransfusion. British Journal of Haematology 1997; 96: 77-79
  2. Campbell PJ, Tirvengadum MA, Pickering W, Cohen H, Ryan KE.HEPTEST: A suitable method for monitoring heparin prophylaxis during pregnancy. Clinical and Laboratory Haematology 1999; 21, 193-199
  3. Campbell P, Iland H, Gibson J, Joshua D. Syngeneic stem cell transplantation for HIV-related lymphoma. British Journal of Haematology 1999; 105: 795-798
  4. Tam C, Seymour J, Brown M, Campbell P, Scarlett J, Underhill C, Ritchie D, Bond R, Grigg A. An analysis of the early and late infectious consequences of the addition of Rituximab to Fludarabine and Cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica 2005; 90:700-702
  5. Field K, McFarlane C, Cheng AC, Hughes AJ, Jacobs E, Styles K, Low J, Stow P, Campbell P, Athan E. Incidence of bloodstream infection and a mechanical valve needle-free system in an Australian Haematology-Oncology Unit. Infection Control and Hospital Epidemiology 2007 May; 28(5): 610-613
  6. Saravanan L, Brennan S, George P, Lowen R, Kirkland M, Campbell P. Novel Fibrinogen Aa chain mutation associated with afibrinogenemia. Pathology. October 2007; 39(5): 519-520
  7. Azad A, Campbell P. High rates of infection associated with the use of maintenance Rituximab monotherapy in non-Hodgkin lymphoma. Internal Medicine Journal. 2009 November; 39:778-779
  8. Kenealy M, Seymour JF, Cowan L, Milner A, Giri P, Ho SJ, Benson W, Nicol A, Campbell P, Prosser I, Underhill C, Cunningham I, Mills A, Szer J, Presgrave P, Filshie R. The tolerability of combination therapy with Thalidomide and 5-Azacitidine in patients with advanced myelodysplastic syndromes (MDS). Blood 2009. 114(22); 1749A
  9. Fung CY, Grigoriadis G, Hocking J, Campbell P, Schwarer AP, Walker PA, Avery S, Patil SS, Salem HH, Spencer A, Wei A. Initial remission duration is the most important predictor of outcome following FLAG-Amsacrine salvage of AML in first relapse. Blood 2011. 118; 3631
]]>
jurydog@gmail.com (Melbourne Haematology) Haematologists Thu, 13 Sep 2012 13:45:18 +1000
Dr Andre Simmance https://melbournehaematology.com.au/haematologists/dr-andre-simmance.html https://melbournehaematology.com.au/haematologists/dr-andre-simmance.html Dr Andre Simmance
Dr Andre Simmance consults at: Geelong - Barwon Health

Andrew Love Cancer Centre
Barwon Health
Geelong VIC 3220
Tel: 03 4215 2700

Map of Rooms LocationView Map of Room's Location

MBBS FRACP FRCPA

  • Consultant Haematologist

Dr Andre Simmance completed his medical degree at Monash University, and undertook clinical and laboratory haematology training through Monash Medical Centre and Austin Health.

He currently holds a clinical haematologist appointment at Geelong Hospital and a laboratory haematologist appointment at Healthscope Pathology.

His interests include general and malignant haematology, haemostasis and thrombosis.


Dr Simmance is a fellow of the Royal College of Pathologists of Australasia and the Royal Australasian College of Physicians, and a member of the Haematology Society of Australia and New Zealand, and the European Haematology Association.


"Andre's interests include general and malignant haematology, haemostasis and thrombosis."


]]>
jurydog@gmail.com (Melbourne Haematology) Haematologists Fri, 14 Sep 2012 11:43:11 +1000